Current ANZUP trials
Bladder Cancer PCR MIB Trial
Opened in mid-2016, this trial is aimed at managing bladder cancer that has spread into the wall of the bladder. A combination of chemotherapy and radiotherapy is the current standard treatment. This study aims to assess if it is safe and effective to add an additional new drug called pembrolizumab to the standard therapy of chemotherapy and radiation therapy.
Current site locations for the PCR MIB ANZUP clinical trial:
Pembrolizumab is a new treatment that “takes the brakes off” the immune system, allowing it to attack cancers more effectively. Studies of pembrolizumab in widespread bladder cancer have shown benefit, with cancer shrinkage observed in about two thirds of people, and in some cases long periods of disease control. At present, pembrolizumab, is approved for use in Australia for the treatment of advanced melanoma in adults.
VIC
It is expected that it will take two years to accrue the required 30 patients. To date, we have four sites active and recruiting. Please speak with your doctor if this is of interest to you or someone you know. For more information, please go to the trials page on the ANZUP website: https://www.anzup.org.au/ content.aspx?page=bladdercancertrialdetails
34 A LITTLE BELOW THE BELT
NSW • Prince of Wales Hospital • Chris O’Brien Lifehouse
• Austin Hospital WA • Sir Charles Gairdner Hospital